Essentials · Evidence reviewed
Can you switch from Wegovy to Zepbound?
People sometimes consider changing medicines because of side effects, inadequate response, cost or insurance. Wegovy contains semaglutide and Zepbound contains tirzepatide. They are different medicines, so switching is a prescribing decision—not a simple conversion of one milligram number into another.
Are the doses equivalent?
No standard milligram-for-milligram conversion between semaglutide and tirzepatide is established by their FDA prescribing labels. Even if a person has used a high dose of one medicine, that does not automatically mean they should start at a high dose of the other.
What does the clinician need to review?
The prescriber should examine your current product and dose, treatment history, response, adverse effects, other medicines, medical conditions and gaps since the last dose. The two products have different initiation and escalation instructions, warnings and contraindications.
What about overlapping treatment?
Don't take both weight-loss GLP-1-related prescriptions together unless a qualified prescriber has specifically evaluated the situation; overlapping treatment can create safety problems. Ask for explicit directions on when to stop the previous medication and when to begin the next.
Will insurance approve the replacement?
A new prescription can trigger different prior authorization requirements, product exclusions or pharmacy pricing. Check the exact formulation and indication with your insurer before assuming the new medicine will cost the same.
The bottom line
Switching may be considered by a clinician, but there is no safe universal dose-conversion chart for everyone.
Written and published by MyDosePro as an educational explanation of publicly available evidence. We identify trial registrations separately from published results and do not provide individual prescribing advice.
Primary sourceCurrent Wegovy prescribing information ↗
Additional evidenceThis guide explains published evidence; source dates may be older than the review date. Our interpretation is educational and does not replace medical or insurance advice.